



Corporate Overview

When Every Second Counts, CardioGenics' Improved Cardiac Testing Reduces Heart Attack Diagnosis Time From 2.8 Hours To Fifteen Minutes

Coronary heart disease is the number one cause of death in high income and low-income countries. The current diagnostic process for heart attack is time-consuming, taking an average of 2.8 hours to confirm the diagnosis of a heart attack, using lab based immunodiagnosics. If a patient doesn't receive treatment during the "golden hour," the first hour of a heart attack, the chance of recovery decreases significantly.

CardioGenics Inc. was founded in Toronto in 1997 by Dr. Yahia Gawad to develop technology and products targeting the immunoassay segment of the IVD testing market. To date, the company has developed the following products:

- Proprietary method for improving the light collection from **Paramagnetic Beads ("Beads")**; Distribution deal signed with Merck & Co.
- **QL Care® Analyzer ("QLCA")**, a state-of-the-art proprietary point-of-care ("POC") immunoanalyzer; FDA Submission expected in 14 months
- Series of **immunoassay tests** to detect cardiac markers; FDA submission of the first test with **QL Care Analyzer**

Products

QL Care® Analyzer – First CardioGenics Product Expected to Receive FDA Approval

The QLCA represents a shift in the design POC analyzers. The QLCA is small, portable, stand-alone and completely automated point-of-care immunoanalyzer. The QLCA has successfully miniaturized lab test technology, and combined it with a simplified mechanical design and proprietary triggering mechanism. QLCA employ chemiluminescence or light generation, the same technology used by the most complicated lab analyzers.



The QLCA uses our patented core technology to perform immunoassay tests at the POC and employs a disposable test cartridge. Each Cartridge is pre-loaded with our Beads, which have been coated with Silver and also contain specific biologicals for the target marker. Few drops of whole blood added to the Cartridge results in initiating the testing and the light generation (chemiluminescence), needed to deliver sensitive and accurate test results. Operation of the QLCA does not require specialized training and testing can be completed in 15 minutes.

Next Steps with FDA Submission and Commercialization:

Two Steps Away From Market Introduction

The QLCA protocol has been rigorously tested, and we have compared our test results against medical laboratory test data. We have consistently met or exceeded the sensitivity standards of medical laboratory immunoassay equipment. Next steps to approval are as follows:

1. Beta testing at four medical institutions in Ontario and the US
2. Submit FDA application to approve the QLCA and the Tnl test within 12-14 months from September 2009; the remaining tests will be submitted to the FDA at three-month intervals

Commercialization:

Upon FDA approval, we will market the QLCA and the Tests through a major IVD Distributor. We have initiated discussions with a number of the Tier 1 IVD companies, and we anticipate the selection of a partner prior to FDA approval.

Key Statistics

(as of March 2010)

Ticker.....	CGNH.OB
Recent Price	\$0.08
Market Cap	\$45.71M
Shares Outstanding.....	217.66M
Average Volume	156,492
52 Week Range.....	\$0.07-0.78

Management

Yahia Gawad MB, Ch.B., MD, MSc
Chief Executive Officer

James Essex CA, MBA
Chief Financial Officer

Linda Sterling, F.Inst.L.C.O
Corporate Secretary/Director

Investor Relations

The Investor Relations Group
11 Stone Street
New York, NY 10004
Tel.: (212) 825-3210
Fax: (212) 825-3229

Investor Relations

Adam S. Holdsworth
Adam@investorrelationsgroup.com

Media Relations

Laura Colontrelle
lcolontrelle@investorrelationsgroup.com



Paramagnetic Beads: *Distribution Deal Signed with Merck & Co. In 2009*



Our Beads increase the sensitivity and accuracy of immunoassay tests. We use our Beads in a series of self-contained cartridge-based immunoassay tests targeting cardiac markers, the proteins that are present in the blood of patients with certain heart disease.

Our Beads represent a significant product advance. Most paramagnetic beads are made of iron oxide, and are traditionally black or brown. We have developed a proprietary process that coats the Beads with a layer of silver, making them white, and more sensitive to light. We have tested our Beads against all commercially available beads, and our silver-coated Beads are five times more sensitive than traditional black or brown magnetic particles.

Series of Immunoassay Follow-on Tests: *FDA Submission Pending Approval of QLCA*

To support the use of the QLCA, we have developed four immunoassay tests designed to identify cardiac markers, specific proteins present in the blood at the time of a heart attack and heart failure. Following FDA approval, these tests will be designed to administer sequentially in the diagnostic process and the management of patients with heart disease. The full scope of our core technology, as well as the know-how we have developed with regard to chemical entrapment in bioassays, are covered under our patent web.


Tests And Descriptions:

Troponin I (TnI)

- TnI testing is the current routine testing for a heart attack.
- TnI is a heart muscle protein, released in the bloodstream shortly after a heart attack (myocardial infarction or MI)
- Current laboratory analyzers cannot detect TnI before 4-6 hours after the onset of symptoms
- Our test will take only 15 minutes to deliver quantitative results, allowing physicians to obtain much more rapid results

Plasminogen Activator Inhibitor Type-1 (PAI-1)

- This test will help to optimize the performance of a heart drug, (tPA, tissue plasminogen activator) a clot buster used as the first line of therapy for MI patients
- This proprietary whole blood test will quantify PAI-1 levels within 15 minutes minimize the trial and error methods now used by doctors to optimize drugs best suited to each patient



Heart Failure Risk Stratification (HFRS)

- We have discovered a family of related proteins that are released into the bloodstream during heart failure
- We are developing a proprietary test, to stratify the risk of death in patients with heart failure, thus permitting the initiation of appropriate therapy at an early stage

Large Market Opportunity



- In Vitro Diagnostic (IVD) testing market = **\$42 billion** (2007)
- **Immunoassay** testing represents **28%** of the IVD testing
- The worldwide market for **Paramagnetic Beads** in IVD testing is in excess of **\$1 billion**
- Market penetration of current quantitative **POC testing** is poor due to a lack of an analyzer that delivers lab-quality results
- Multinational IVD companies are **seeking current CardioGenics products** to add to their product line

Disclaimer

The information disseminated by the Investor Relations Group ("IRG" or "we") is for informational purposes only and is neither a solicitation to buy nor an offer to sell securities. We do not undertake or purport to render any investment advice or recommendations for the buying and selling of securities. Companies that are profiled may have engaged our services to perform investor relations services, including promotional services, and the placement of their profiled companies on our website IRG compensation for such services has been or will be made in cash and issuance of securities of the profiled company, the amount or type of compensation is available upon request. We may liquidate any securities that we receive as compensation when deemed appropriate to do so. The assembled information herein is based on information supplied by the company, press releases, SEC filings and other sources believed to be reliable as of the date of the report on the featured companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. It is subject to change without notice. IRG and its affiliates are not, nor claim to be: brokers, broker-dealers, market makers, investment bankers, advisors, analysts or underwriters. Information in email alerts, fact sheets and other forms of informational media provided by us will contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21 of the Securities Exchange Act of 1934. Forward-looking statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated. The cautionary statements made herein should be read as being applicable to all related forward-looking statements where they appear on this site or in other communications. We encourage you to visit the Securities Exchange Commission Website at <http://www.sec.gov>.